SEC Form 4 · accession 0001179110-15-013364
KYTHERA BIOPHARMACEUTICALS INC · KYTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
III Frederick Beddingfield
Officer — Chief Medical Officer
Period of report
Sep 24, 2015
Accepted (ET)
Sep 28, 2015 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 24, 2015 | M | 96,875 | $22.49 | A | 96,875 | D | |
| Common Stock | Sep 24, 2015 | M | 13,763 | $44.02 | A | 110,638 | D | |
| Common StockF3 | Sep 24, 2015 | S | 110,638 | $74.907 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $22.49 | Sep 24, 2015 | M | 46,875 | D | — | Apr 1, 2023 | Common Stock | 46,875 | 28,125 | D |
| Stock OptionsF2 | $22.49 | Sep 24, 2015 | M | 50,000 | D | — | Apr 1, 2023 | Common Stock | 50,000 | 0 | D |
| Stock OptionsF1 | $44.02 | Sep 24, 2015 | M | 13,763 | D | — | Jan 22, 2024 | Common Stock | 13,763 | 19,266 | D |
Explanation of responses
- F125% of the shares subject to the option vested on the first anniversary measured from January 1, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- F2The shares subject to these options vested 100% upon the achievement of certain performance milestones approved by the Issuer's Board of Directors.
- F3The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $74.90 to $74.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.